Related Experiment Videos
Abstract:
(1) A variety of antibiotics can be used to treat community-acquired Gram-positive pneumonia. In contrast, for the treatment of nosocomial pneumonia and complicated skin and soft-tissue infections the choice of antibiotic must take into account the likely Gram positive species and the local resistance pattern. (2) Linezolid, a member of a new family of antibiotics, the oxazolidinones, has been authorized for all three indications. (3) Available clinical trials include two comparative studies in community-acquired pneumonia, one comparative study in nosocomial pneumonia, two comparative studies in complicated skin and soft-tissue infections, and one study in several of these situations. Linezolid was never superior to the comparator antibiotic. Cases of linezolid resistance have been reported. (4) Haematological disturbances are the main adverse effects, especially thrombocytopenia, the precise frequency of which remains unknown. (5) Linezolid is a non selective monoamine oxidase inhibitor (MAOI). It therefore has the potential to interact with several adrenergic and serotoninergic drugs and to cause hypertensive crisis and serotonin syndromes. (6) In practice, linezolid has no place in the treatment of community-acquired pneumonia, for which many antibiotics are already available. Linezolid may be an option, after the quinupristin + dalfopristin combination, for treating nosocomial pneumonia and complicated skin and soft-tissue infections due to multidrug-resistant bacteria, depending on the results of resistance tests.
Insights
Linezolid, an oxazolidinone antibiotic, is not superior to other treatments for community-acquired pneumonia. It may be an option for resistant nosocomial infections but carries risks of resistance and adverse effects.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Antibiotic selection for Gram-positive infections varies by setting.
- Nosocomial pneumonia and complicated skin infections require consideration of local resistance patterns.
- Linezolid (oxazolidinone) is approved for community-acquired pneumonia, nosocomial pneumonia, and skin infections.
Purpose of the Study:
- To evaluate the efficacy and safety of linezolid.
- To compare linezolid with existing antibiotic treatments.
- To assess linezolid's role in treating specific Gram-positive bacterial infections.
Main Methods:
- Review of available clinical trials.
- Comparative studies in community-acquired pneumonia (2 studies).
- Comparative studies in nosocomial pneumonia (1 study) and complicated skin/soft-tissue infections (2 studies).
Main Results:
- Linezolid demonstrated no superiority over comparator antibiotics in trials.
- Reported cases of linezolid resistance exist.
- Key adverse effects include hematological disturbances, particularly thrombocytopenia.
Conclusions:
- Linezolid is not recommended for community-acquired pneumonia due to available alternatives.
- Linezolid may be considered for multidrug-resistant nosocomial pneumonia and skin infections, post-quinupristin/dalfopristin therapy, pending resistance testing.
- Linezolid's MAOI properties necessitate caution due to potential drug interactions and hypertensive crisis risk.